Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on discovering and commercializing medicines for central nervous system and neurological disorders. The company's commercial portfolio includes NUPLAZID, the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis, and DAYBUE, an FDA-approved treatment for Rett syndrome available in oral solution and powder formulation (DAYBUE STIX). Acadia maintains a robust pipeline addressing significant unmet medical needs, with mid- to late-stage programs in development for Alzheimer's disease psychosis and Lewy body dementia psychosis, alongside earlier-stage neurological and rare disease programs. Founded in 1993 and headquartered in San Diego, California, the company serves patients, healthcare providers, and the global medical community by advancing therapeutic options for underserved patient populations in neurological and rare disease segments.